What is Evogene's earnings per share (EPS)?

Evogene (EVGN) reported diluted earnings per share of -$1.70 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Evogene Financials

EVGN

FY2025 annual

Revenue $3.9M -30.9% YoY

Net Income -$7.8M +56.6% YoY

EPS (Diluted) -$1.70 YoY not available

Free Cash Flow -$13.6M +32.9% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 26, 2026 Currency USD FYE December

Evogene (EVGN) reported $3.9M in revenue for fiscal year 2025, down 30.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EVGN FY2025 2026-08-15

Evogene’s filings show an asset-light business still living on balance-sheet resources, even as cash burn has begun to ease.

From FY2024 to FY2025, revenue fell but both net loss and operating cash use improved, so the business did not get healthier by scaling sales; it got leaner. FY2025 operating cash flow of -$13.5M was almost the same size as year-end cash of $13.0M, making burn control the central financing issue.

Year-end cash fell only from $15.3M to $13.0M, which can look calmer than the operating picture really was. That stability came alongside investing inflows of $17.7M, meaning FY2025 liquidity was supported by non-operating sources rather than by the core business turning cash-generative.

Capex was just $135K versus free cash flow of -$13.6M, so this is not a capital-hungry model where equipment spending explains the cash drain. After the FY2024 squeeze, the current ratio rebounded to 4.5x, showing short-term obligations look manageable even though the operation itself still consumes cash.

Financial Health Signals

Financial health score not available

Evogene does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/8

Evogene passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Evogene reported a net loss of $7.8M while operations used $13.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.9M

YoY-30.9%

5Y CAGR+29.9%

10Y CAGR-10.1%

Evogene generated $3.9M in revenue in fiscal year 2025. This represents a decrease of 30.9% from the prior year.

Net Income

-$7.8M

YoY+56.6%

Evogene reported -$7.8M in net income in fiscal year 2025. This represents an increase of 56.6% from the prior year.

EPS (Diluted)

-$1.70

Evogene earned -$1.70 per diluted share (EPS) in fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$13.6M

YoY+32.9%

Evogene recorded an outflow of $13.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 32.9% from the prior year.

Cash & Debt

$13.0M

YoY-15.3%

5Y CAGR-22.5%

10Y CAGR+2.4%

Evogene held $13.0M in cash against $1.5M in long-term debt as of fiscal year 2025.

Shares Outstanding

Evogene had 9M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-65.4%

YoY+56.3pp

5Y CAGR-19.3pp

10Y CAGR-48.8pp

Evogene's ROE was -65.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 56.3 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

Capital Expenditures

$135K

YoY-78.4%

5Y CAGR-27.7%

10Y CAGR-23.6%

Evogene invested $135K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 78.4% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

Share Buybacks

Not reported for fiscal year 2025.

EVGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EVGN quarterly income statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Revenue	$3.9M-30.9%	$5.6M+87.0%	$3.0M+78.0%	$1.7M+80.1%	$930K-10.6%	$1.0M+38.1%	$753K-56.9%	$1.7M-48.3%	$3.4M-48.3%	$6.5M-41.2%	$11.1M
Interest Expense	$183K+173.1%	$67K-41.7%	$115K-30.3%	$165K-47.6%	$315K+32.4%	$238K-21.2%	$302K	N/A	N/A	N/A	N/A
Income Tax	$1K-88.9%	$9K-52.6%	$19K-78.9%	$90K+592.3%	$13K-59.4%	$32K+33.3%	$24K-20.0%	$30K+172.7%	$11K-69.4%	$36K	N/A
Net Income	-$7.8M+56.6%	-$18.1M+30.4%	-$26.0M+13.0%	-$29.8M+2.0%	-$30.4M-16.2%	-$26.2M-37.1%	-$19.1M+8.2%	-$20.8M+0.1%	-$20.8M-6.4%	-$19.6M-13.8%	-$17.2M
EPS (Diluted)	-$1.70	-$2.47	-$4.56	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).

EVGN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EVGN quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Total Assets	$20.0M-49.7%	$39.9M-22.0%	$51.1M-9.0%	$56.1M-26.4%	$76.3M+6.1%	$71.9M+0.8%	$71.4M+21.6%	$58.7M-24.4%	$77.6M-19.2%	$96.0M	N/A
Current Assets	$15.6M-27.6%	$21.6M-37.4%	$34.5M-8.7%	$37.8M-33.6%	$56.9M+9.8%	$51.8M+5.7%	$49.0M-11.6%	$55.5M-23.8%	$72.8M-18.7%	$89.5M	N/A
Cash & Equivalents	$13.0M-15.3%	$15.3M-26.3%	$20.8M-28.3%	$29.0M-10.3%	$32.3M-30.1%	$46.2M+33.0%	$34.7M+498.1%	$5.8M+69.1%	$3.4M+6.1%	$3.2M-68.3%	$10.2M
Inventory	$210K-88.5%	$1.8M+2293.4%	$76K-86.6%	$566K+515.2%	$92K	$0	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.1M-67.7%	$25.0M+11.6%	$22.4M+5.1%	$21.3M+65.6%	$12.9M-14.3%	$15.0M+34.9%	$11.1M+32.9%	$8.4M+2.0%	$8.2M-5.4%	$8.7M	N/A
Current Liabilities	$3.4M-81.6%	$18.7M+169.2%	$6.9M+23.4%	$5.6M-18.3%	$6.9M-28.9%	$9.7M+68.4%	$5.7M+5.8%	$5.4M+16.4%	$4.7M-10.7%	$5.2M	N/A
Long-Term Debt	$1.5M-22.6%	$1.9M+571.6%	$285K-69.4%	$932K-45.0%	$1.7M+1.9%	$1.7M-19.9%	$2.1M	N/A	N/A	N/A	N/A
Total Equity	$12.0M-19.3%	$14.8M-48.3%	$28.7M-17.5%	$34.8M-45.1%	$63.4M+11.5%	$56.9M-5.5%	$60.2M+19.7%	$50.3M-27.5%	$69.4M-20.5%	$87.3M-15.9%	$103.8M
Retained Earnings	-$282.6M-3.1%	-$274.1M-6.4%	-$257.6M-10.2%	-$233.7M-12.9%	-$207.1M-15.5%	-$179.3M-15.0%	-$155.9M-13.1%	-$137.8M-17.7%	-$117.0M-21.7%	-$96.2M	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Total Assets	$20.0M-40.9%	$33.9M-14.9%	$39.9M-2.7%	$41.0M-19.8%	$51.1M-4.2%	$53.3M-5.0%	$56.1M-0.9%	$56.7M
Current Assets	$15.6M-45.4%	$28.6M+32.7%	$21.6M-16.2%	$25.8M-25.2%	$34.5M-3.5%	$35.7M-5.4%	$37.8M+0.1%	$37.7M
Cash & Equivalents	$13.0M+55.6%	$8.3M-45.6%	$15.3M+61.3%	$9.5M-54.3%	$20.8M+2.7%	$20.2M-30.2%	$29.0M+0.4%	$28.9M
Inventory	$210K-89.3%	$2.0M+7.5%	$1.8M+129.1%	$794K+944.7%	$76K-69.5%	$249K-56.0%	$566K+249.4%	$162K
Total Liabilities	$8.1M-62.5%	$21.6M-13.9%	$25.0M+19.0%	$21.0M-6.2%	$22.4M+0.8%	$22.2M+4.2%	$21.3M+89.4%	$11.3M
Current Liabilities	$3.4M-77.3%	$15.2M-18.7%	$18.7M+14.8%	$16.3M+134.5%	$6.9M+8.7%	$6.4M+13.6%	$5.6M+1.5%	$5.5M
Long-Term Debt	$1.5M-25.1%	$2.0M+3.4%	$1.9M+659.5%	$252K-11.6%	$285K-51.3%	$585K-37.2%	$932K-31.8%	$1.4M
Total Equity	$12.0M-3.2%	$12.4M-16.6%	$14.8M-25.6%	$19.9M-30.5%	$28.7M-7.8%	$31.1M-10.6%	$34.8M-23.4%	$45.4M
Retained Earnings	-$282.6M-0.5%	-$281.1M-2.6%	-$274.1M-2.7%	-$266.9M-3.6%	-$257.6M-4.3%	-$247.0M-5.7%	-$233.7M-4.3%	-$224.2M

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.

EVGN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EVGN quarterly cash flow statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Operating Cash Flow	-$13.5M+31.5%	-$19.7M+8.7%	-$21.6M+8.9%	-$23.7M+4.2%	-$24.7M-26.7%	-$19.5M-10.5%	-$17.7M-16.5%	-$15.2M+4.8%	-$15.9M-36.2%	-$11.7M+5.8%	-$12.4M
Capital Expenditures	$135K-78.4%	$626K+8.5%	$577K-50.7%	$1.2M+38.3%	$847K+24.2%	$682K-24.2%	$900K+140.6%	$374K-36.6%	$590K-27.0%	$808K-59.7%	$2.0M
Free Cash Flow	-$13.6M+32.9%	-$20.3M+8.3%	-$22.2M+10.8%	-$24.8M+2.8%	-$25.6M-26.6%	-$20.2M-8.8%	-$18.6M-19.5%	-$15.5M+6.0%	-$16.5M-32.1%	-$12.5M+13.3%	-$14.4M
Investing Cash Flow	$17.7M+84.3%	$9.6M+312.0%	-$4.5M-134.2%	$13.3M+164.5%	-$20.6M-318.4%	$9.4M-74.6%	$37.1M+114.0%	$17.4M+13.8%	$15.2M+278.5%	$4.0M-76.8%	$17.4M
Financing Cash Flow	-$6.6M-241.8%	$4.7M-74.3%	$18.2M+94.3%	$9.3M-69.1%	$30.3M+48.6%	$20.4M+118.9%	$9.3M+3033.3%	$297K-63.5%	$814K+24.3%	$655K+1355.6%	$45K

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22

Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

EVGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

EVGN quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Net Margin	-203.1%	-323.7%	-870.4%	-1781.7%	-3273.7%	-2519.8%	-2538.5%	-1191.3%	-616.3%	-299.6%	-154.7%
Return on Equity	-65.4%+56.3pp	-121.7%-31.2pp	-90.5%-4.7pp	-85.8%-37.8pp	-48.0%-1.9pp	-46.1%-14.3pp	-31.7%+9.6pp	-41.4%-11.3pp	-30.0%-7.6pp	-22.4%-5.8pp	-16.6%
Return on Assets	-39.1%+6.2pp	-45.3%+5.5pp	-50.8%+2.4pp	-53.2%-13.3pp	-39.9%-3.5pp	-36.4%-9.6pp	-26.8%+8.7pp	-35.5%-8.6pp	-26.9%-6.4pp	-20.4%	N/A
Current Ratio	4.54+3.4x	1.15-3.8x	4.96-1.7x	6.71-1.6x	8.27+2.9x	5.36-3.2x	8.53-1.7x	10.22-5.4x	15.61-1.5x	17.13	N/A
Debt-to-Equity	0.120.0x	0.13+0.1x	0.010.0x	0.030.0x	0.030.0x	0.030.0x	0.03-0.1x	0.170.0x	0.120.0x	0.10	N/A
FCF Margin	-353.9%	-364.5%	-742.9%	-1483.5%	-2748.7%	-1941.9%	-2465.6%	-889.2%	-488.6%	-191.2%	-129.5%

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Current Ratio	4.54+2.7x	1.89+0.7x	1.15-0.4x	1.58-3.4x	4.96-0.6x	5.59-1.1x	6.71-0.1x	6.80
Debt-to-Equity	0.120.0x	0.160.0x	0.13+0.1x	0.010.0x	0.010.0x	0.020.0x	0.030.0x	0.03

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.

Similar Companies

Ernexa ERNA

$5.7M

Lyra Therapeutics, Inc. LYRA

$2.3M

Moleculin Biotec MBRX

$11.9M

Mustang Bio MBIO

$4.2M

Kazia Therapeuti KZIA

$157.6M

Where Evogene Ranks

Frequently Asked Questions

What is Evogene's annual revenue?

Evogene (EVGN) reported $3.9M in total revenue for fiscal year 2025. This represents a -30.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Evogene's revenue growing?

Evogene (EVGN) revenue declined by 30.9% year-over-year, from $5.6M to $3.9M in fiscal year 2025.

Is Evogene profitable?

No, Evogene (EVGN) reported a net income of -$7.8M in fiscal year 2025.

How much debt does Evogene have?

As of fiscal year 2025, Evogene (EVGN) had $13.0M in cash and equivalents against $1.5M in long-term debt.

What is Evogene's return on equity (ROE)?

Evogene (EVGN) has a return on equity of -65.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Evogene's free cash flow?

Evogene (EVGN) recorded an outflow of $13.6M in free cash flow during fiscal year 2025. This represents a 32.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Evogene's operating cash flow?

Evogene (EVGN) recorded an outflow of $13.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Evogene's total assets?

Evogene (EVGN) had $20.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Evogene's capital expenditures?

Evogene (EVGN) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Evogene have outstanding?

Evogene (EVGN) had 9M shares outstanding as of fiscal year 2025.

What is Evogene's current ratio?

Evogene (EVGN) had a current ratio of 4.54 as of fiscal year 2025, which is generally considered healthy.

What is Evogene's debt-to-equity ratio?

Evogene (EVGN) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Evogene's return on assets (ROA)?

Evogene (EVGN) had a return on assets of -39.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Evogene's Piotroski F-Score?

Evogene (EVGN) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Evogene's earnings high quality?

Evogene (EVGN) reported a net loss of $7.8M while operations used $13.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.